Evidence map›Paper›PMID 33491305›Full record

ArticleObesity (Silver Spring, Md.)2021

The Role of Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease.

Marita Kalaoja, Laura J Corbin, Vanessa Y Tan, Ari V Ahola-Olli, Aki S Havulinna, Kristiina Santalahti, Niina Pitkänen, Terho Lehtimäki, Leo-Pekka Lyytikäinen, Emma Raitoharju and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Obesity (Silver Spring, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Marita Kalaoja *Computational Medicine, Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.ORCID 0000-0002-0755-7296
Laura J Corbin *MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.ORCID 0000-0002-4032-9500
Vanessa Y Tan *MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.ORCID 0000-0001-7938-127X
Ari V Ahola-OlliStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Aki S HavulinnaFinnish Institute for Health and Welfare, Helsinki, Finland.
Kristiina SantalahtiMedicity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.
Niina PitkänenResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Terho LehtimäkiDepartment of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
Leo-Pekka LyytikäinenDepartment of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
Emma RaitoharjuDepartment of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
Ilkka SeppäläDepartment of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
Mika KähönenDepartment of Clinical Physiology, Tampere University Hospital, Tampere, Finland.
Samuli RipattiInstitute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland.
Aarno PalotieStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Markus PerolaInstitute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland.
Jorma S ViikariDepartment of Medicine, University of Turku, Turku, Finland.
Sirpa JalkanenMedicity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.
Mikael MaksimowMedicity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.
Veikko SalomaaFinnish Institute for Health and Welfare, Helsinki, Finland.
Marko SalmiMedicity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.
Olli T RaitakariResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Johannes Kettunen *Computational Medicine, Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
Nicholas J Timpson *MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.ORCID 0000-0002-7141-9189
University of Turku · FITampere University · FIBroad Institute · USFinnish Institute for Health and Welfare · FIUniversity of Bristol · GBUniversity of Helsinki · FIUniversity of Oulu · FI

Funding

Cancer Research UK 19169Cancer Research UK C18281/A19169Medical Research Council MC_UU_00011/1Wellcome Trust 202802/Z/16/Z
6 · The paper itself

Abstract

objectiveThis study aimed to investigate the role of cytokines as intermediates in the pathway from increased adiposity to disease.

methodsBMI and circulating levels of up to 41 cytokines were measured in individuals from three Finnish cohort studies (n = 8,293). Mendelian randomization (MR) was used to assess the impact of BMI on circulating cytokines and the impact of BMI-driven cytokines on risk of obesity-related diseases.

resultsObservationally, BMI was associated with 19 cytokines. For every SD increase in BMI, causal effect estimates were strongest for hepatocyte growth factor, monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and were as ratios of geometric means 1.13 (95% CI: 1.08-1.19), 1.08 (95% CI: 1.04-1.14), and 1.13 (95% CI: 1.04-1.21), respectively. TRAIL was associated with a small increase in the odds of coronary artery disease (odds ratio: 1.03; 95% CI: 1.00-1.06). There was inconsistent evidence for a protective role of MCP-1 against inflammatory bowel diseases.

conclusionsObservational and MR estimates of the effect of BMI on cytokine levels were generally concordant. There was little evidence for an effect of raised levels of BMI-driven cytokines on disease. These findings illustrate the challenges of MR when applied in the context of molecular mediation.

Indexed as

AdiposityBody Mass IndexCohort StudiesCytokinesHumansObesityCytokines

Identifiers

PMID33491305
PMCPMC8614117
OpenAlexW3123171685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.